Precision Antibody
Precision Antibody is a leading provider of custom antibody development services, with over 24 years of experience and more than 20,000 successful projects delivered to over 500 organizations worldwide. The company specializes in rapid, high-quality, application-specific monoclonal and polyclonal antibody development, production, and characterization, serving pharmaceutical, biotech, academic, and government clients. Precision Antibody is recognized for its proprietary technologies, award-winning services, and a success rate exceeding 95% in delivering antibodies that perform as intended. Accredited by AAALAC and OLAW, the company is committed to strict quality control, confidentiality, and milestone-based, transparent pricing. Their mission is to enable scientific advancement through innovative, reliable, and tailored antibody solutions.
Precision Antibody
9130 Red Branch Road, Suite X, Columbia, MD 21045
What We Do
Mouse monoclonal antibody specific to SARS-CoV-2 S1 protein (non-RBD region), does not cross-react with SARS-CoV-1 or MERS. Recognizes trimeric and monomeric forms, validated for protein Simple, Western Blot, ELISA, and Immunoprecipitation.
Mouse monoclonal antibodies against Plasmodium falciparum HRP2, validated for ELISA, used in malaria rapid diagnostic tests. Includes four clones, validated in Analytical Biochemistry 534 (2017) 10-13.
Mouse monoclonal antibody against human ACE2 protein, suitable for Protein Simple Wes, Western blot, ELISA, and immunoprecipitation.
Mouse monoclonal antibody against Plasmodium falciparum HRP2, validated for ELISA, used in malaria diagnostics. Validated in Analytical Biochemistry 534 (2017) 10-13.
Mouse monoclonal antibody specific for androgen receptor variant 7 (AR-V7), cross-reacts with human, validated for Western Blot and IHC. Reference: Cancer Res 2009; 69: (1). January 1, 2009 16-22.
Mouse monoclonal antibody against Plasmodium falciparum HRP2, validated for ELISA, used in malaria diagnostics. Validated in Analytical Biochemistry 534 (2017) 10-13.
Mouse monoclonal antibody against GP88/Progranulin, validated for ELISA and IHC. Reference: Breast Cancer Research 2012, 14:R26 (8 February 2012).
Mouse monoclonal antibody against MYC tag peptide, validated for ELISA, Western Blot, and Immunoprecipitation.
Mouse monoclonal antibody against MAP1S (C19ORF5), validated for ELISA, Western Blot, and Immunoprecipitation. Reference: Cancer Research 65(10): 4191-4201, 2005.
Mouse monoclonal antibody against GST fusion protein, validated for ELISA and Western Blot.
Mouse monoclonal antibody against Plasmodium falciparum HRP2, validated for ELISA and used in malaria rapid diagnostic tests. Validated in Analytical Biochemistry 534 (2017) 10-13.
Mouse monoclonal antibody against Plasmodium falciparum HRP2, validated for ELISA and used in malaria rapid diagnostic tests. Validated in Analytical Biochemistry 534 (2017) 10-13.
Recombinant human GP88/Progranulin protein, >95% purity by SDS-PAGE, available in liquid or lyophilized form. Used in oncology research and diagnostics.
Formalin-fixed paraffin-embedded cell slides for IHC, positive and negative controls for GP88/Progranulin expression. Used in breast cancer research and diagnostics.
ELISA kit for the detection and quantification of GP88/Progranulin, used in oncology research and clinical studies.
Mouse monoclonal antibody against 6X-HIS tag, validated for ELISA and Western Blot applications.
Mouse monoclonal antibodies targeting SARS-CoV-2, available for research and diagnostic applications. Please inquire for details.
Mouse monoclonal antibodies against SARS-CoV-2 nucleocapsid protein, suitable for Protein Simple Wes, Western blot, ELISA, and immunoprecipitation.
Mouse monoclonal antibodies against the receptor binding domain (RBD) of SARS-CoV-2 S1 protein, available in multiple clones and formats.
Development of novel mono- and polyclonal antibodies in 30-60 days, including Mouse & Rat monoclonal antibodies, Fully Human monoclonal antibodies, Humanized monoclonal antibodies, and polyclonal antibodies from Rat, Rabbit, and Goat. Project strategies are customized to ensure delivery of antibodies that work in intended applications.
Production and purification of antibodies from hybridomas, stable cell lines, or transiently transfected cells in serum-free media, as well as from ascites. Offers milligram to gram-scale production, affinity purification, buffer exchange, concentration adjustment, and delivery with Certificate of Analysis.
Determination of antibody biochemical and biophysical characteristics, including binding characteristics by Octet or Biacore, to select the best antibodies for intended applications.
Includes antibody class and subclass determination, isoelectric point determination, detection of oligomers by analytical SEC, VH and VL sequencing, humanization, cell banking, conjugation, stability assay, and epitope mapping.
Specialized in vivo and in vitro assays to evaluate antibody performance, including ligand neutralization assays, receptor internalization assays, various biological assays, FLOW-based assay, IHC, custom EIA, and Oncology Panel Profiler.
Development of fully human antibodies using transgenic mice, capable of generating large numbers of antigen-specific clones producing fully human IgG in about 60 days.
Development of anti-idiotypic antibodies for pharmacokinetic and pharmacodynamic studies, using proprietary immunization protocols for improved generation.
Application Area
Diagnostics
Digital Health Technologies
Services
Key People
President & Founder
News & Updates
Precision Antibody is accredited by AAALAC and OLAW, ensuring the highest standards of quality and care in laboratory practices.
The company has delivered more than 20,000 successful antibody development projects to over 500 contracted organizations worldwide.
Recognized for award-winning services in custom antibody development and production.
Utilizes proprietary technologies for rapid, high-quality antibody development, including Smart Fusion technology and exclusive licensing for trans-chromosomic mice.
Preferred and long-term service provider for leading global pharmaceutical and biotechnology companies, as well as government institutions.
Explores how mammalian cell banks reduce risks, ensure compliance, and support success in biopharma production.
Discusses when and why preclinical programs should consider engineered antibodies for optimal results.
Describes how functional assays can predict clinical trial outcomes and boost regulatory confidence.
Explains the importance of screening and characterization in ensuring efficacy and accelerating drug success.
Highlights the growing importance of rigorous antibody characterization in biomedical research.
Compares fully human and humanized antibodies for safety, efficacy, and speed in drug development.
Guides researchers in selecting the appropriate assay for antibody validation and research.
Outlines key qualities to look for in a contract research organization for antibody drug discovery.
Explores antibody engineering, including humanization, ADCs, bispecifics, and strategies for therapeutic use.
Details the benefits of fully human monoclonal antibodies in drug development, including safety and efficacy.
Describes Precision Antibody's approach to rapid and effective custom antibody development for drug discovery.
Explains the role of custom polyclonal antibodies in research and diagnostics.
Discusses the importance of biochemical and molecular characterization in antibody development.
Explores the benefits of early antibody humanization for drug safety, cost, and development speed.
Describes how humanized antibodies enhance safety and success in therapeutic applications.
Explains the significance of functional assays in validating antibody-based drugs.
Comprehensive guide on the stages and benefits of custom antibody development for therapeutics.
Discusses the impact of custom anti-idiotype antibodies on precision, safety, and efficiency in drug development.
Highlights the advantages of fully human monoclonal antibodies in therapeutic development.
Overview of the importance and process of custom antibody development in medicine and research.
Compares traditional cancer treatments with monoclonal antibody therapies.
Describes the use of trans-chromosomic mice and proprietary technology to develop fully human antibodies rapidly.
Precision Antibody's contribution to the development of novel antibody reagents for the RAS signaling network as part of the National Cancer Institute’s RAS initiative.
An overview of fully human monoclonal antibody development, highlighting their effectiveness in complex disease treatment and the process from concept to clinical application.
Explores six key benefits of custom antibody development for targeting difficult antigens, enhancing research, diagnostics, and therapeutic advancements.
Discusses the importance of antibody purification for achieving consistent results in biotechnology applications.
Explains how custom polyclonal antibodies, with their ability to recognize multiple epitopes, are essential for advanced therapeutic discovery.
Describes the impact of fully human monoclonal antibodies on cancer therapy, offering targeted and effective treatment options.
Provides a checklist for biotech teams to select the right antibody purification partner for quality and compliance.
Highlights the foundational role of mammalian cell banking in producing high-quality antibodies for biopharmaceuticals.
Provides tips and strategies for maintaining antibody stability during long-term storage to prevent degradation.
Discusses why mammalian cell banking is essential for antibody development, ensuring consistency and risk protection.
Identifies common mistakes in outsourcing antibody development and how to avoid them for faster therapeutic success.
Dr. Ginette Serrero, CEO of A&G Pharmaceutical Inc., DBA Precision Antibody, presented two posters at the American Association of Cancer Research’s annual meeting.